Erschienen in:
01.12.2014 | Original Article
Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancer
verfasst von:
Toru Aoyama, Yusuke Katayama, Masaaki Murakawa, Masahiro Asari, Amane Kanazawa, Akio Higuchi, Manabu Shiozawa, Satoshi Kobayashi, Makoto Ueno, Manabu Morimoto, Shinnichi Ohkawa, Makoto Akaike, Naoto Yamamoto, Takaki Yoshikawa, Yasushi Rino, Munetaka Masuda, Soichiro Morinaga
Erschienen in:
Cancer Chemotherapy and Pharmacology
|
Ausgabe 6/2014
Einloggen, um Zugang zu erhalten
Abstract
Background
The factors which affect the 6-month continuation of adjuvant chemotherapy with S-1 have not been fully evaluated in pancreatic cancer. The objective of this retrospective study was to clarify the risk factors for the discontinuation of S-1 adjuvant chemotherapy after 6 months of treatment.
Methods
The study included patients who underwent curative surgery for pancreatic cancer, were diagnosed with stage II or III disease, had a serum creatinine level ≤1.2 mg/dl and received adjuvant S-1 between June 2007 and March 2014.
Results
Forty patients were eligible for the present study. A comparison of the 6-month continuation stratified by each clinical factor using the log-rank test revealed a significant difference in the creatinine clearance (CCr) between the patients who continued and discontinued the treatment. A CCr of 60 ml/min was regarded as a critical point. The uni- and multivariate Cox’s proportional hazard analyses demonstrated that the CCr was the only significant independent predictive factor. The 6-month continuation rate was 70.8 % in the patients with a CCr ≥60 ml/min and was 25.0 % in patients with a CCr <60 ml/min (P = 0.008). The patients with a CCr <60 ml/min developed adverse events more frequently and earlier than those with a CCr ≥60 ml/min.
Conclusions
A CCr < 60 ml/min was a significant risk factor for the 6-month discontinuation of S-1 adjuvant chemotherapy in pancreatic cancer patients, even though the renal function was judged to be normal based on the serum creatinine level. Careful attention is therefore required to improve the S-1 continuation in patients with a CCr < 60 ml/min.